Phase I/II study of oral immunotherapy with Cry j1-galactomannan conjugate for Japanese cedar pollinosis

Auris Nasus Larynx

Volumn 41, Issue 4, 2014, Pages 350-358

  Murakami, Daisuke ^a,d   Kubo, Kazuhiko ^a,e   Sawatsubashi, Motohiro ^a   Kikkawa, Sayaka ^a   Ejima, Masayoshi ^a,f   Saito, Akira ^b   Kato, Akio ^c   Komune, Shizuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Bio business Propulsion Division   (Japan)

^c YAMAGUCHI UNIVERSITY   (Japan)

^d SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^e Chidoribashi Byoin   (Japan)

^f KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

Author keywords

Adverse effects; Clinical efficacy; Cry j1 galactomannan conjugate; Japanese cedar pollinosis; Oral immunotherapy

Indexed keywords

ANTIALLERGIC AGENT; CRY J1 GALACTOMANNAN; IMMUNOGLOBULIN G4; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTIBODY; CRY J I PROTEIN, CRYPTOMERIA JAPONICA; CYTOKINE; GALACTOMANNAN; MANNAN; PLANT ANTIGEN; VEGETABLE PROTEIN;

ABDOMINAL PAIN; ADULT; ALLERGIC RHINITIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DESENSITIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; EYELID EDEMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; JAPANESE CEDAR; LARYNGOPHARYNGEAL DYSESTHESIA; MALAISE; MALE; NAUSEA; ORAL IMMUNOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLLEN ALLERGY; PRURITUS; RHINITIS; RHINOCONJUNCTIVITIS; SIDE EFFECT; SNEEZING; SYMPTOMATOLOGY; URTICARIA; VOMITING; BIOSYNTHESIS; CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PROCEDURES; RHINITIS, ALLERGIC, SEASONAL;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES; ANTIGENS, PLANT; CRYPTOMERIA; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MANNANS; MIDDLE AGED; PLANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL;

EID: 84899977538     PISSN: 03858146     EISSN: 18791476     Source Type: Journal    
DOI: 10.1016/j.anl.2014.02.010     Document Type: Article

References (30)

1. Bousquet J., Van Cauwenberge P., Khaltaev N., Aria Workshop Group Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:S147-S334. World Health Organization.
2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998, 351:1225-1232.
3. Okuda M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003, 91:288-296.
4. Kaneko Y., Motohashi Y., Nakamura H., Endo T., Eboshida A. Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis. Int Arch Allergy Immunol 2005, 136:365-371.
5. Di Bona D., Plaia A., Leto-Barone M.S., La Piana S., Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol 2012, 130:1097-1107.
6. Scadding G.W., Shamji M.H., Jacobson M.R., Lee D.I., Wilson D., Lima M.T., et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010, 40:598-606.
7. Weiner H.L. Oral tolerance. Proc Natl Acad Sci USA 1994, 91:10762-10765.
8. Suko M., Mori A., Ito K., Okudaira H. Oral immunotherapy may induce T cell anergy. Int Arch Allergy Immunol 1995, 107:278-281.
9. Chehade M., Mayer L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 2005, 115:3-12.
10. Yasueda H., Yui Y., Shimizu T., Shida T. Isolation and partial characterization of the major allergen from Japanese cedar (Cryptomeria japonica) pollen. J Allergy Clin Immunol 1983, 71:77-86.
11. Usui M., Saito A., Taniguchi N., Nishijima N., Azakami H., Kato A. Reduction of antigenicity of Cry j I, major allergen of Japanese cedar pollen, by the attachment of polysaccharides. Biosci Biotechnol Biochem 2003, 67:2425-2430.
12. Aoki R., Saito A., Azakami H., Kato A. Effects of various saccharides on the masking of epitope sites and uptake in the gut of cedar allergen Cry j1-saccharide conjugates by a naturally occurring Maillard reaction. J Agric Food Chem 2010, 58:7986-7990.
13. Arita K., Babiker E.E., Azakami H., Kato A. Effect of chemical and genetic attachment of polysaccharides to proteins on the production of IgG and IgE. J Agric Food Chem 2001, 49:2030-2036.
14. Mailing H.J., Weeke B. Position paper: immunotherapy. Allergy 1993, 48:9-35.
15. Okubo K., Kurono Y., Fujieda S., Ogino S., Uchio E., Odajima H., et al. Japanese guideline for allergic rhinitis. Allergol Int Off J Jpn Soc Allergol 2011, 60:171-189.
16. Practical guideline for the management of allergic rhinitis in Japan 2013, Life Science, Tokyo, [in Japanese]. 7th ed. M. Okuda, A. Konno, H. Takenaka, R. Kishikawa, H. Odajima, K. Okubo (Eds.).
17. + regulatory T cells at the single-cell level. Eur J Immunol 2005, 35:1681-1691.
18. Moller C., Dreborg S., Lanner A., Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986, 41:271-279.
19. Jones S.M., Pons L., Roberts J.L., Scurlock A.M., Perry T.T., Kulis M., et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009, 124:292-300.
20. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006, 61:151-165.
21. Hawrylowicz C.M., O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005, 5:271-283.
22. Jeannin P., Lecoanet S., Delneste Y., Gauchat J.F., Bonnefoy J.Y. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998, 160:3555-3561.
23. + cell numbers in atopic patients and healthy control subjects. J Allergy Clin Immunol 2007, 120:960-962.
24. Yamanaka K., Yuta A., Kakeda M., Sasaki R., Kitagawa H., Gabazza E.C., et al. Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J Allergy Clin Immunol 2009, 124:842-845.
25. Bjorksten B., Moller C., Broberger U., Ahlstedt S., Dreborg S., Johansson S.G., et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy 1986, 41:290-295.
26. Taudorf E., Laursen L.C., Lanner A., Bjorksten B., Dreborg S., Soborg M., et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987, 80:153-161.
27. Canonica G.W., Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003, 111:437-448.
28. Xu X., Brining D., Rafiq A., Hayes J., Chen J.D. Effects of enhanced viscosity on canine gastric and intestinal motility. J Gastroenterol Hepatol 2005, 20:387-394.
29. Schonfeld J., Evans D.F., Wingate D.L. Effect of viscous fiber (guar) on postprandial motor activity in human small bowel. Dig Dis Sci 1997, 42:1613-1617.
30. Passalacqua G., Durham S.R. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007, 119:881-891. Global Allergy and Asthma European Network.